217 related articles for article (PubMed ID: 10680790)
1. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
Sanders DB; Massey JM; Sanders LL; Edwards LJ
Neurology; 2000 Feb; 54(3):603-7. PubMed ID: 10680790
[TBL] [Abstract][Full Text] [Related]
2. 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS.
Oh SJ; Claussen GG; Hatanaka Y; Morgan MB
Muscle Nerve; 2009 Nov; 40(5):795-800. PubMed ID: 19722254
[TBL] [Abstract][Full Text] [Related]
3. 3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials.
Zhang N; Hong D; Ouyang T; Meng W; Huang J; Li M; Hong T
BMC Neurol; 2021 Sep; 21(1):371. PubMed ID: 34563155
[TBL] [Abstract][Full Text] [Related]
4. Treatment for Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J
Cochrane Database Syst Rev; 2003; (2):CD003279. PubMed ID: 12804456
[TBL] [Abstract][Full Text] [Related]
5. Treatment for Lambert-Eaton myasthenic syndrome.
Keogh M; Sedehizadeh S; Maddison P
Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD003279. PubMed ID: 21328260
[TBL] [Abstract][Full Text] [Related]
6. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.
Wirtz PW; Titulaer MJ; Gerven JM; Verschuuren JJ
Expert Rev Clin Immunol; 2010 Nov; 6(6):867-74. PubMed ID: 20979551
[TBL] [Abstract][Full Text] [Related]
7. Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.
Oh SJ; Shcherbakova N; Kostera-Pruszczyk A; Alsharabati M; Dimachkie M; Blanco JM; Brannagan T; Lavrnić D; Shieh PB; Vial C; Meisel A; Komoly S; Schoser B; Sivakumar K; So Y;
Muscle Nerve; 2016 May; 53(5):717-25. PubMed ID: 26852139
[TBL] [Abstract][Full Text] [Related]
8. 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).
Sanders DB
Ann N Y Acad Sci; 1998 May; 841():811-6. PubMed ID: 9668334
[No Abstract] [Full Text] [Related]
9. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
Quartel A; Turbeville S; Lounsbury D
Curr Med Res Opin; 2010 Jun; 26(6):1363-75. PubMed ID: 20377318
[TBL] [Abstract][Full Text] [Related]
10. Treatment for Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J
Cochrane Database Syst Rev; 2005 Apr; (2):CD003279. PubMed ID: 15846654
[TBL] [Abstract][Full Text] [Related]
11. Effect of 3,4-diaminopyridine on the time course of decay of compound muscle action potential augmentation in the Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J; Mills KR
Muscle Nerve; 1998 Sep; 21(9):1196-8. PubMed ID: 9703446
[TBL] [Abstract][Full Text] [Related]
12. Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.
Lundh H; Nilsson O; Rosén I; Johansson S
Acta Neurol Scand; 1993 Aug; 88(2):136-40. PubMed ID: 8213058
[TBL] [Abstract][Full Text] [Related]
13. Amifampridine Phosphate (Firdapse) Is Effective in a Confirmatory Phase 3 Clinical Trial in LEMS.
Shieh P; Sharma K; Kohrman B; Oh SJ
J Clin Neuromuscul Dis; 2019 Mar; 20(3):111-119. PubMed ID: 30801481
[TBL] [Abstract][Full Text] [Related]
14. Treatment in Lambert-Eaton myasthenic syndrome.
Maddison P
Ann N Y Acad Sci; 2012 Dec; 1275():78-84. PubMed ID: 23278581
[TBL] [Abstract][Full Text] [Related]
15. 3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome.
Lee MK; Sunwoo IN; Kim SM
J Clin Neurosci; 2018 Apr; 50():194-198. PubMed ID: 29402568
[TBL] [Abstract][Full Text] [Related]
16. [Long-term treatment of Lambert-Eaton syndrome by 3, 4 diaminopyridine].
Jost WH; Mielke U; Forrett-Kaminsky MC; Schimrigk K
Rev Neurol (Paris); 1992; 148(12):776-9. PubMed ID: 1303573
[TBL] [Abstract][Full Text] [Related]
17. 3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis.
Sanders DB; Howard JF; Massey JM
Ann N Y Acad Sci; 1993 Jun; 681():588-90. PubMed ID: 8357206
[No Abstract] [Full Text] [Related]
18. Amifampridine for the Management of Lambert-Eaton Myasthenic Syndrome: A New Take on an Old Drug.
Yoon CH; Owusu-Guha J; Smith A; Buschur P
Ann Pharmacother; 2020 Jan; 54(1):56-63. PubMed ID: 31319693
[No Abstract] [Full Text] [Related]
19. 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.
Sanders DB; Juel VC; Harati Y; Smith AG; Peltier AC; Marburger T; Lou JS; Pascuzzi RM; Richman DP; Xie T; Demmel V; Jacobus LR; Aleš KL; Jacobus DP;
Muscle Nerve; 2018 Apr; 57(4):561-568. PubMed ID: 29280483
[TBL] [Abstract][Full Text] [Related]
20. Amifampridine to treat Lambert-Eaton myasthenic syndrome.
Oh SJ
Drugs Today (Barc); 2020 Oct; 56(10):623-641. PubMed ID: 33185628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]